Background—We recently suggested that many anticardiolipin antibodies bind only to
oxidized cardiolipin (OxCL) and/or to OxCL–β2-glycoprotein 1 (β2GP1) adducts but not to a …

Circulating autoantibodies to phospholipids (aPLs), such as cardiolipin (CL), are found in
patients with antiphospholipid antibody syndrome (APS). We recently demonstrated that …

β2-Glycoprotein I (β2-GPI) is a major antigen for anticardiolipin antibodies (aCL) induced in
patients with antiphospholipid syndrome and their antigenic epitopes are cryptic. The …

The optimal clinical management of patients with antiphospholipid antibody syndrome (APS)
is uncertain because of a lack of an underlying hypothesis to explain why antiphospholipid …

The clinical and serological features of 38 aCL‐positive patients were compared to those of
45 aCL‐negative patients. A significantly higher incidence of thrombophlebitis and livedo …

Contrary to infective anticardiolipin (aCL) antibodies, autoimmune aCL antibodies react with
phospholipids (PL) mainly via binding to the plasma glycoprotein cofactor β 2-Glycoprotein I …

Antiphospholipid antibodies in autoimmune sera have been shown to react with a complex
of phospholipids (cardiolipin) and a plasma phospholipid-binding protein, β2-glycoprotein I …

Background Recurrent arterial thrombosis and venous thrombosis are frequent
complications of the antiphospholipid syndrome (APS). Patients produce anti-cardiolipin …

Anticardiolipin (aCL) and anti-beta2-glycoprotein I (antiβ2GPI) antibodies have been shown
in animal models as not cross-reacting antibody populations. This observation prompted us …

Previous studies have shown a cross-reaction between anticardiolipin and anti-oxidized low-
density lipoprotein (LDL) antibodies in patients with the antiphospholipid syndrome (APS) …